This occurs by means of the portal inflow of TLR-4 and TLR-9 agonists in mice, leading to heightened hepatic tumor necrosis factor alpha (TNF-α) expression and inflammation, a phenomenon particularly pronounced in mouse models of hepatic steatosis [26]. Here, TLR4 is linked to fatty liver disease.